In a patient with unexplained weight loss and a CT‑identified lytic destructive lesion of the right iliac bone without prior orthopedic surgery, should a positron emission tomography/computed tomography (PET/CT) scan be obtained?

Yes, obtain a PET/CT scan to evaluate the extent of disease and identify the primary malignancy

In a patient with unexplained weight loss and a lytic destructive iliac bone lesion on CT, you should proceed with FDG-PET/CT imaging to determine the full extent of skeletal involvement and identify potential primary tumor sites. This approach is supported by multiple guidelines emphasizing that when bone metastases are suspected or incidentally identified, whole-body metabolic imaging is indicated to assess disease distribution 1, 2.

Why PET/CT is the Appropriate Next Step

The combination of a lytic destructive lesion with constitutional symptoms (weight loss) raises significant concern for metastatic disease. FDG-PET/CT offers several critical advantages in this scenario:

• Superior detection of lytic lesions: FDG-PET directly assesses metabolic activity of tumor cells rather than relying on osteoblastic response, making it particularly effective for purely osteolytic metastases 3
• Whole-body staging: Identifies the primary tumor source and maps the complete extent of skeletal and extra-skeletal disease in a single examination 1
• Higher diagnostic accuracy: PET imaging demonstrates superior diagnostic accuracy, higher spatial resolution, and shorter imaging times compared to conventional bone scintigraphy 1

Important Caveats About Lytic Lesions

Traditional bone scans have limited sensitivity for purely lytic lesions (62-100% sensitivity, with lowest values in predominantly lytic disease) because they depend on osteoblastic activity 3. Since your CT shows a lytic destructive lesion, bone scintigraphy would be suboptimal. FDG-PET/CT is specifically advantageous for lytic metastases because it detects early malignant bone marrow infiltration through increased glucose metabolism before significant bone remodeling occurs 3.

The Diagnostic Algorithm

1. Obtain FDG-PET/CT for comprehensive staging and primary tumor identification
2. Correlate with clinical history: Age ≥40 years warrants workup for metastatic disease including chest/abdomen/pelvis CT if not already performed 4
3. Consider tissue diagnosis: With bone-only disease or equivocal imaging, CT-guided biopsy is strongly recommended to confirm metastasis and assess biomarkers 1
4. Additional laboratory studies: CBC, comprehensive metabolic panel with calcium, alkaline phosphatase, and tumor markers based on suspected primary (PSA, SPEP, etc.) 4

Critical Pitfalls to Avoid

• Do not rely on bone scan alone: Bone scintigraphy is relatively insensitive for purely osteolytic lesions commonly seen in renal, thyroid, and multiple myeloma metastases 3
• PET is not 100% specific: Requires careful integration with CT morphological findings to avoid false positives from benign processes 1
• Slowly proliferating lesions may be missed: Some low-grade tumors with minimal metabolic activity can show false-negative results 1
• Multiple myeloma exception: If myeloma is suspected, low-dose whole-body CT or FDG-PET/CT are preferred over bone scan, which often misses myeloma bone disease 1

When to Obtain Biopsy

Histological confirmation is strongly recommended in bone-only disease, especially with few or equivocal lesions 1. The biopsy should be CT-guided when feasible and provides opportunity to reassess biomarkers that may direct therapy. This is particularly important given the major clinical and emotional consequences of a metastatic bone disease diagnosis 1.

The presence of weight loss combined with a destructive lytic lesion creates high clinical suspicion for malignancy, making comprehensive staging with PET/CT the most appropriate next step before considering biopsy or treatment planning 2, 4.